Rexulti (Brexpiprazole): How This Antipsychotic Works and When Telehealth Is Enough

Last updated: August 20, 2026

Rexulti (brexpiprazole) is a second-generation (atypical) antipsychotic used as add-on treatment for major depressive disorder in adults, for schizophrenia in adults and adolescents 13 and older, and for agitation linked to dementia due to Alzheimer’s disease. Tablets come in 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, and 4 mg strengths. Most people take it once daily with or without food. This guide covers how brexpiprazole works, label dosing ranges, side effects and boxed warnings, drug interactions, and when online psychiatry may be enough for evaluation and follow-up.

See if online depression or mood care may be a fit →

Browse Klarity condition pages →

What is Rexulti (brexpiprazole)?

Brexpiprazole is an atypical antipsychotic. According to MedlinePlus, clinicians prescribe it for schizophrenia, for depression together with another antidepressant, and for agitation in people with dementia due to Alzheimer’s disease. It changes activity of certain natural substances in the brain, mainly dopamine and serotonin pathways.

NAMI describes brexpiprazole as a second-generation antipsychotic (SGA) that rebalances dopamine and serotonin to improve thinking, mood, and behavior. FDA-labeled uses NAMI highlights include schizophrenia, adjunctive treatment of major depressive disorder (added to an antidepressant), and treatment of agitation associated with dementia due to Alzheimer’s disease.

Brand tablet strengths listed by NAMI:

• Rexulti oral tablets: 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg

Whether brand or a later generic option is preferred depends on your plan’s formulary and prior authorization rules, not on Klarity’s clinical preference alone. Coverage for Rexulti may vary by plan; verify benefits before you assume a specific copay.

How brexpiprazole works

Brexpiprazole is often discussed alongside other dopamine partial-agonist antipsychotics (a group that also includes aripiprazole). Clinically, the goal is to stabilize dopamine and serotonin signaling rather than fully shut dopamine down. That does not make the medicine “mild” or free of risk. It still carries the class warnings of atypical antipsychotics and needs medical supervision.

MedlinePlus notes that brexpiprazole may control symptoms but does not cure the underlying condition. Continue the medicine even if you feel better, and do not stop without a plan from your prescriber. NAMI states it may take two to three months before you feel the full effect, while some schizophrenia symptoms (hallucinations, disorganized thinking, delusions) may start to improve in the first 1-2 weeks.

FDA-labeled uses

Per the DailyMed REXULTI prescribing information (updated May 6, 2026), REXULTI is an atypical antipsychotic indicated for:

• Adjunctive therapy to antidepressants for major depressive disorder (MDD) in adults
• Schizophrenia in adults and pediatric patients ages 13 years and older
• Agitation associated with dementia due to Alzheimer’s disease

Limitation of use: REXULTI is not indicated as an as-needed (“prn”) treatment for agitation associated with dementia due to Alzheimer’s disease.

Your clinician matches the indication, age, and dose to your history. Off-label uses exist in practice; those decisions belong in a documented clinical relationship, not in a blog post.

Typical oral dosing (label ranges)

Always follow the dose on your prescription. The DailyMed highlights table lists these oral ranges (once daily, with or without food):

• MDD, adults (adjunct to an antidepressant): start 0.5 mg/day or 1 mg/day; recommended target 2 mg/day; maximum 3 mg/day
• Schizophrenia, adults: start 1 mg/day; recommended target 2 to 4 mg/day; maximum 4 mg/day
• Schizophrenia, pediatric (13-17 years): start 0.5 mg/day; recommended target 2 to 4 mg/day; maximum 4 mg/day
• Agitation associated with dementia due to Alzheimer’s disease: start 0.5 mg/day; recommended target 2 mg/day; maximum 3 mg/day

NAMI notes the usual dose range is about 0.5 mg to 4 mg, with slow titration over weeks. Only your clinician can set the correct dose for you.

Organ function caps (DailyMed):

• Moderate to severe hepatic impairment: max 2 mg once daily for MDD or Alzheimer’s-related agitation; max 3 mg once daily for schizophrenia
• CrCl under 60 mL/minute: same maximums as hepatic impairment above

Dose also changes for CYP2D6 poor metabolizers and when you take strong CYP2D6 or CYP3A4 inhibitors or inducers. Those adjustments sit in the full label section 2.7; your pharmacist and prescriber apply them.

MedlinePlus instructions:

• Take once a day at about the same time
• Take with or without food
• If you miss a dose, take it when you remember unless it is almost time for the next dose; do not double up

Drug interactions

Brexpiprazole is metabolized in pathways that include CYP2D6 and CYP3A4. According to NAMI, levels may rise with:

• Clarithromycin
• Antidepressants such as fluoxetine, paroxetine, and nefazodone
• Azole antifungals such as fluconazole, ketoconazole, and itraconazole
• Quinidine
• Certain HIV protease inhibitors (for example indinavir, ritonavir, saquinavir, lopinavir/ritonavir)

Levels may fall with inducers such as carbamazepine and rifampin. MedlinePlus also flags St. John’s wort as an herbal product that may interact. Brexpiprazole may block effects of Parkinson’s medicines such as levodopa/carbidopa and some dopamine agonists. Share a full medication and supplement list at every visit.

Side effects and serious risks

Common effects NAMI lists include restlessness (akathisia), weight gain, and cholesterol changes. MedlinePlus also notes drowsiness, tiredness, dizziness, and balance problems.

Serious risks (call your clinician or seek emergency care when these appear) include allergic reactions; seizures; signs of infection; fever with stiff muscles, confusion, and sweating (possible neuroleptic malignant syndrome); uncontrolled movements of the face or body (tardive dyskinesia or other extrapyramidal symptoms); trouble swallowing; and falls from dizziness or sedation.

Atypical antipsychotics can raise blood sugar, weight, and lipids (metabolic syndrome). MedlinePlus stresses watching for extreme thirst, frequent urination, extreme hunger, blurred vision, or weakness. Some people develop intense urges (gambling, shopping, sex, binge eating); family members should know this risk because the person taking the medicine may not notice the change.

Brexpiprazole may make it harder to cool down in heat and may cause orthostatic dizziness when you stand quickly. Avoid alcohol and recreational drugs, which can worsen sedation and undercut benefit.

Boxed warnings you should know

The DailyMed label carries boxed warnings:

• Increased mortality in elderly patients with dementia-related psychosis. Antipsychotics raise the risk of death in this group. REXULTI is not approved for dementia-related psychosis without agitation associated with dementia due to Alzheimer’s disease.
• Suicidal thoughts and behaviors. Antidepressants increase that risk in pediatric and young adult patients. Closely monitor anyone treated with antidepressants for worsening mood or new suicidal thoughts. Safety and effectiveness of REXULTI have not been established in pediatric patients with MDD.

If you or someone you care for has thoughts of self-harm, call or text 988 (Suicide & Crisis Lifeline) or go to the nearest emergency department.

How Rexulti compares with related medicines

People often research Rexulti next to other atypical antipsychotics used for mood or psychosis. Klarity has patient-facing guides on:

• Abilify (aripiprazole)
• Vraylar (cariprazine)
• Seroquel (quetiapine)
• Wellbutrin (bupropion) and other antidepressants often paired when Rexulti is used as an adjunct

Choice among these medicines depends on diagnosis, prior response, side-effect profile, metabolic risk, drug interactions, cost, and formulary status. No blog post can rank one drug as “best” for every person.

When telehealth may be enough

HHS Telehealth notes that telehealth is an effective tool that expands access to behavioral health services, and that use of telehealth for behavioral health may increase access, continuity, privacy, and convenience while reducing barriers such as stigma. A survey of mental health treatment facilities found that 80% offered care via telehealth.

For many adults on a stable oral atypical antipsychotic or starting adjunctive treatment for depression, video visits can support history-taking, side-effect review, medication adjustments within label ranges, and coordination with therapy. In-person care is still the safer path when someone is acutely psychotic and unsafe, needs long-acting injectable administration, has unstable medical issues (for example uncontrolled diabetes or cardiac symptoms), or requires urgent labs or imaging your telehealth team cannot complete remotely.

Klarity connects patients with a network of 2,000+ licensed providers. A visit does not guarantee a Rexulti prescription. Clinicians decide based on your history, exam, state rules, and whether the medicine is appropriate.

Check whether online depression treatment may work for you →

Insurance, cost, and prior authorization

Rexulti is often a brand specialty-tier medicine. Plans may require step therapy (trying other antipsychotics or antidepressants first), prior authorization, or quantity limits. Coverage may vary by commercial plan, Medicaid, and Medicare Part D. Klarity does not promise that any specific plan will cover Rexulti or set your copay.

Practical steps:

• Ask your plan for the formulary tier and prior authorization criteria
• Ask the pharmacy about manufacturer savings programs if you have commercial insurance
• Bring denial letters to your clinician so medical necessity documentation can address the plan’s exact rules

Disclaimer: This article is educational and is not medical advice, a diagnosis, or a guarantee of insurance coverage. Medication decisions require a licensed clinician who knows your full history. Always verify benefits with your insurer before you rely on a specific coverage outcome.

Frequently asked questions

Is Rexulti an antidepressant or an antipsychotic?

Rexulti is an atypical antipsychotic. For depression, the FDA labels it as adjunctive therapy: it is added to an antidepressant, not used alone as first-line monotherapy for MDD on the label.

How long does Rexulti take to work?

NAMI notes that some schizophrenia symptoms may improve in 1-2 weeks, while full benefit may take 2-3 months. Depression adjunct response timelines vary; your clinician sets follow-up intervals to judge benefit versus side effects.

Does Rexulti cause weight gain?

Weight gain and metabolic changes are recognized risks with second-generation antipsychotics, including brexpiprazole. MedlinePlus recommends periodic weight checks. Diet, activity, and lab monitoring of glucose and lipids are part of responsible care.

Can I get Rexulti through an online doctor?

In many states, licensed telehealth clinicians may evaluate mood and psychotic disorders and prescribe when clinically appropriate. Controlled-substance rules are less often the blocker for Rexulti (it is not a DEA scheduled controlled substance on the DailyMed label), but medical appropriateness, monitoring, and state practice rules still apply. Acute safety issues may still need in-person or emergency care.

What should I do if I feel restless on Rexulti?

Akathisia (inner restlessness) is a common reason people stop atypical antipsychotics. Do not stop abruptly on your own. Contact your prescriber; dose changes, timing changes, or a different medicine may help.

Related Klarity reading

• Depression treatment online
• Trintellix (vortioxetine)
• Auvelity
• Pristiq (desvenlafaxine)
• All condition hubs

Start a visit to discuss mood or antipsychotic options with a licensed provider →

Sources: MedlinePlus: Brexpiprazole; NAMI: Brexpiprazole (Rexulti); DailyMed: REXULTI (brexpiprazole); HHS: Telehealth for behavioral health. Always defer to your clinician and the current FDA label for dosing and safety.